FMP
SeaStar Medical Holding Corporation
ICU
NASDAQ
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
1.26 USD
0.015 (1.19%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
135k
135k
135k
135k
135k
135k
Revenue %
-
-
-
-
-
-
-
-
-
Ebitda
-
-
-11.61M
-11.14M
-24.58M
81k
81k
81k
81k
81k
Ebitda %
100
100
100
100
-18.21k
60
60
60
60
Ebit
-6.45M
-4.45M
-23.22M
-25.15M
-24.58M
81k
81k
81k
81k
81k
Ebit %
100
100
100
100
-18.21k
60
60
60
60
Depreciation
6.45M
4.45M
11.61M
14.01M
-
108k
108k
108k
108k
108k
Depreciation %
100
100
100
100
-
80
80
80
80
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
2.81M
510k
47k
176k
1.82M
135k
135k
135k
135k
135k
Total Cash %
100
100
100
100
1.35k
100
100
100
100
Receivables
-
58k
12k
-
112k
130.4k
130.4k
130.4k
130.4k
130.4k
Receivables %
100
100
100
100
82.96
96.59
96.59
96.59
96.59
Inventories
55k
-
-
-
-
108k
108k
108k
108k
108k
Inventories %
100
100
100
100
-
80
80
80
80
Payable
382k
85k
1.93M
4.37M
3.05M
135k
135k
135k
135k
135k
Payable %
100
100
100
100
2.26k
100
100
100
100
Cap Ex
-
-
-
-
-
-
-
-
-
-
Cap Ex %
100
100
100
100
-
-
-
-
-
Weighted Average Cost Of Capital
Price
1.26
Beta
Diluted Shares Outstanding
4.92M
Costof Debt
42.51
Tax Rate
After Tax Cost Of Debt
42.51
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
574k
Total Equity
6.22M
Total Capital
6.8M
Debt Weighting
8.44
Equity Weighting
91.56
Wacc
8.17
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
135k
135k
135k
135k
135k
135k
Ebitda
-
-
-11.61M
-11.14M
-24.58M
81k
81k
81k
81k
81k
Ebit
-6.45M
-4.45M
-23.22M
-25.15M
-24.58M
81k
81k
81k
81k
81k
Tax Rate
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Ebiat
-6.47M
-4.45M
-23.22M
-25.15M
-24.59M
81k
81k
81k
81k
81k
Depreciation
6.45M
4.45M
11.61M
14.01M
-
108k
108k
108k
108k
108k
Receivables
-
58k
12k
-
112k
130.4k
130.4k
130.4k
130.4k
130.4k
Inventories
55k
-
-
-
-
108k
108k
108k
108k
108k
Payable
382k
85k
1.93M
4.37M
3.05M
135k
135k
135k
135k
135k
Cap Ex
-
-
-
-
-
-
-
-
-
-
Ufcf
309.22k
-299.03k
-9.72M
-8.68M
-26.02M
-2.85M
189k
189k
189k
189k
Wacc
8.17
8.17
8.17
8.17
8.17
Pv Ufcf
-2.63M
161.53k
149.33k
138.05k
127.62k
Sum Pv Ufcf
-2.06M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
8.17
Free Cash Flow T1
192.78k
Terminal Value
3.12M
Present Terminal Value
2.11M
Intrinsic Value
Enterprise Value
52.75k
Net Debt
-1.25M
Equity Value
1.3M
Diluted Shares Outstanding
4.92M
Equity Value Per Share
0.26
Projected DCF
0.26376 -3.777%
